Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib

Siraj M. Ali, R. Kathy Alpaugh, Jamie K. Buell, Philip J. Stephens, Jian Qin Yu, Hong Wu, Christine N. Hiemstra, Vincent A. Miller, Doron Lipson, Gary A. Palmer, Jeffrey S. Ross, Massimo Cristofanilli*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations
Original languageEnglish (US)
Pages (from-to)e14-e16
JournalClinical breast cancer
Issue number1
StatePublished - Feb 2014


  • HER2
  • Inflammatory breast cancer
  • Lapatinib
  • Next-generation sequencing
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this